This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.theguardian.com/healthcare-network/2016/jun/01/should-drug-companies-pay-doctors-healthcare-professionals-live-discussion
The article has changed 6 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Should drug companies pay healthcare professionals? Live discussion | Should drug companies pay healthcare professionals? Live discussion |
| (about 7 hours later) | |
| Drug companies pay around £40m a year to healthcare professionals in payments, gifts and hospitality. Payments are made for a number of reasons, including sponsorship of medical education, attendance at medical events or acting as advisers. | Drug companies pay around £40m a year to healthcare professionals in payments, gifts and hospitality. Payments are made for a number of reasons, including sponsorship of medical education, attendance at medical events or acting as advisers. |
| Doctors have always denied that taking drug company money influences their judgement in any way about a medicine, but suspicions have lingered. | Doctors have always denied that taking drug company money influences their judgement in any way about a medicine, but suspicions have lingered. |
| The Association of the British Pharmaceutical Industry (ABPI) says the relationship it has with healthcare professionals “has long been a positive driver for advancements in patient care and the progression of research”. | The Association of the British Pharmaceutical Industry (ABPI) says the relationship it has with healthcare professionals “has long been a positive driver for advancements in patient care and the progression of research”. |
| This year, for the first time, details of payments to UK healthcare professionals are to be published. From June, patients will be able to use a publicly searchable database to find out if a healthcare professional has received any payments from a pharmaceutical company. | This year, for the first time, details of payments to UK healthcare professionals are to be published. From June, patients will be able to use a publicly searchable database to find out if a healthcare professional has received any payments from a pharmaceutical company. |
| This seems to be a popular move among those in the sector; a poll conducted by the Guardian’s Healthcare Professionals Network revealed that 94% of the 247 people who took part agreed that payments by pharmaceutical companies to healthcare professionals should be published. | This seems to be a popular move among those in the sector; a poll conducted by the Guardian’s Healthcare Professionals Network revealed that 94% of the 247 people who took part agreed that payments by pharmaceutical companies to healthcare professionals should be published. |
| Jeremy Hunt, the health secretary, plans to introduce a UK “sunshine rule” (named after the Physician Payment Sunshine Act in the US) on dealings between NHS staff and pharmaceutical firms. | Jeremy Hunt, the health secretary, plans to introduce a UK “sunshine rule” (named after the Physician Payment Sunshine Act in the US) on dealings between NHS staff and pharmaceutical firms. |
| How and why does the pharmaceutical industry work with healthcare professionals? What are the pros and cons of disclosing payments to healthcare professionals? Do the new measures go far enough? What role do healthcare professionals have in improving understanding and openness? What does all of this mean for patients? | How and why does the pharmaceutical industry work with healthcare professionals? What are the pros and cons of disclosing payments to healthcare professionals? Do the new measures go far enough? What role do healthcare professionals have in improving understanding and openness? What does all of this mean for patients? |
| Join us from 1.45 to 3.45pm on Monday 6 June to discuss these questions and more. | Join us from 1.45 to 3.45pm on Monday 6 June to discuss these questions and more. |
| The panel so far | The panel so far |
| Virginia Acha, executive director, research, medical and innovation, ABPI | Virginia Acha, executive director, research, medical and innovation, ABPI |
| Dr Peter Gordon, campaigner for transparency in medicine | Dr Peter Gordon, campaigner for transparency in medicine |
| Dr David Strain, Medical Academics Staff Committee, BMA | Dr David Strain, Medical Academics Staff Committee, BMA |
| Dr Naeem Nazem, medical advisor, MDDUS | Dr Naeem Nazem, medical advisor, MDDUS |
| David Eves, head of compliance, Chugai Pharma Marketing Ltd | David Eves, head of compliance, Chugai Pharma Marketing Ltd |
| Dr Waheed Jamal, vice president – medical, Europe, GlaxoSmithKline plc | |
| The live chat is not video or audio-enabled but will take place in the comments section (below). You may also get in touch via sarah.johnson@theguardian.com or @GdnHealthcare on Twitter. | The live chat is not video or audio-enabled but will take place in the comments section (below). You may also get in touch via sarah.johnson@theguardian.com or @GdnHealthcare on Twitter. |
| Discussion commissioned and controlled by the Guardian, funded by ABPI | Discussion commissioned and controlled by the Guardian, funded by ABPI |
| Join the Healthcare Professionals Network to read more pieces like this. And follow us on Twitter (@GdnHealthcare) to keep up with the latest healthcare news and views. | Join the Healthcare Professionals Network to read more pieces like this. And follow us on Twitter (@GdnHealthcare) to keep up with the latest healthcare news and views. |